By now, the European Medicines Agency (EMA) has authorized the use of capmatinib and tepotinib in patients with advanced-stage NSCLC harboring a MET exon 14 skipping mutation after prior treatment with immunotherapy and/or platinum-based chemotherapy.18 The gene discussed is MET; the disease is non-small cell lung carcinoma.